Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-Center Study to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination With Anti-cancer Agents in Participants With Advanced/Metastatic Solid Tumors

NCT06535607 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06535607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06535607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-Center Study to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination With Anti-cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Recruiting
Start date
August 22, 2024
Completion date
November 30, 2028
Enrollment
257 (estimated)
Sites
98

Conditions

As the registry lists them; a condition with its own page is linked.

sub-study 1 cervical cancer (volrustomig monotherapy), sub-study 2 head and neck squamous cell carcinoma (volrustomig monotherapy), sub-study 3 head and neck squamous cell carcinoma (volrustomig in combination with chemotherapy), sub-study 4 esophageal squamous cell carcinoma (volrustomig in combination with chemotherapy), sub-study 5 unresectable pleural mesothelioma (volrustomig monotherapy)